Short answer
Theravance Biopharma, Inc. (TBPH) filed an 8-K current report with the SEC on September 18, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Shareholders approved Zymeworks merger proposal with 40,993,370 votes for and 8,671 against.
Theravance Biopharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Shareholders approved Zymeworks merger proposal with 40,993,370 votes for and 8,671 against
- 79.14% participation established quorum, with 41,086,774 of 51,918,754 shares represented
- Approval satisfies a key closing condition for Theravance becoming Zymeworks’ wholly owned subsidiary
- Merger expected around September 23, 2026, subject to remaining closing conditions
- Advisory merger-related executive compensation approved, with 40,587,829 votes for and 470,381 against
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Theravance Biopharma, Inc. 8-K filings
Get the next TBPH 8-K as it lands
Follow TBPH for push alerts, or ask the research agent what this filing means.